EE693 Assessing the Impact of Additional Follow-up From the CheckMate-274 Trial on the Cost-Effectiveness (CE) Profile of Nivolumab Versus Surveillance in High-Risk, Muscle-Invasive Urothelial Carcinoma (MIUC)
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.958
https://www.valueinhealthjournal.com/article/S1098-3015(23)04088-3/fulltext
Title :
EE693 Assessing the Impact of Additional Follow-up From the CheckMate-274 Trial on the Cost-Effectiveness (CE) Profile of Nivolumab Versus Surveillance in High-Risk, Muscle-Invasive Urothelial Carcinoma (MIUC)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)04088-3&doi=10.1016/j.jval.2023.09.958
First page :
Section Title :
Open access? :
No
Section Order :
10449